Every 8-K that VYCOR MEDICAL INC (VYCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VYCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VYCO filings page.
Vycor Medical, Inc. reported weaker results for the three and six months ended June 30, 2026. Second‑quarter revenue was $418,264, down 16% from 2025, as Vycor Medical (VBAS) revenue fell 17% to $401,224, mainly from softer international demand, while development‑stage NovaVision revenue grew 17% to $17,040. Q2 gross profit declined to $344,445, with gross margin at 82% versus 83% a year earlier.
For Q2 2026, operating income on a GAAP basis was $6,851, but the company recorded a net loss of $(22,288), compared with net income of $23,887 in 2025, primarily due to interest expense and discontinued operations. On a non‑GAAP basis (excluding depreciation of purchased assets and stock‑based compensation), Q2 cash operating expenses were $321,492, non‑GAAP operating profit was $22,952, and non‑GAAP net loss was $(6,187). For the first half of 2026, revenue decreased 6% to $876,804, gross profit declined 8% to $719,598, GAAP operating income was $52,659, and the net loss available to common stockholders was $(164,365). Weighted average shares outstanding were 33,372,796.
Vycor Medical, Inc. reported results for the three months ended March 31, 2026, highlighted in an earnings press release furnished with this report. Revenue was $458,540, up 5% from $436,378 in 2025, driven mainly by international growth in the Vycor Medical (VBAS) division.
VBAS revenue was $440,441, a 5% increase, while NovaVision generated $18,099 with high gross margin. On a GAAP basis, total operating expenses were $329,345, producing operating income of $45,808 and a net loss available to common stockholders of $(142,077), or $(0.00) per share. Non-GAAP cash operating expenses were $315,365, non-GAAP operating profit was $59,788, and non-GAAP net loss was $(128,097), reflecting improvements versus 2025.
Vycor Medical, Inc. reported 2025 revenue of $1,863,400, up 17% from 2024, driven mainly by international growth in its Vycor Medical (VBAS) neurosurgery business. VBAS revenue reached $1,796,070, an 18% increase, while NovaVision contributed $67,330.
Gross profit rose to $1,561,107 with an 83% margin, down from 89% in 2024 due to new production, shipping, and higher international mix. On a GAAP basis, Vycor generated operating income of $33,900 but recorded a net loss available to common stockholders of $396,796, or $0.01 per share, after preferred dividends.
Excluding non-cash depreciation and stock-based compensation, non-GAAP cash operating expenses were $1,415,226 and non-GAAP operating profit improved to $145,881. Non-GAAP net loss available to common shareholders narrowed to $284,815, or $0.01 per share, indicating better underlying operating performance despite continued net losses.
Vycor Medical, Inc. furnished an Item 2.02 report announcing a press release with financial results for the three and nine months ended September 30, 2025.
The release includes non-GAAP measures—Cash Operating Expenses and Cash Operating Loss—which exclude Depreciation and non-cash Stock Compensation, with reconciliations to comparable GAAP measures. The press release is attached as Exhibit 99.1, and the information is furnished and not deemed “filed” under the Exchange Act.